Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall tone reflects a positive reception, with posts emphasizing the potential of acasunlimab in enhancing antitumor activity, using words like 'cutting-edge', 'boost', and 'potentiates', which indicate strong interest and perceived impact. References to specific elements such as Fc-inert design and combination with PD-1 inhibitors suggest a moderate level of deep engagement among those discussing the publication.
Most discussions recognize the potential and benefits of the new antibody combination, indicating general support for the publication's findings.
Posts show high enthusiasm and curiosity about the innovative nature of the therapy, highlighting interest in its implications.
Participants engage by referencing specifics like the Fc-inert design and immune modulatory effects, demonstrating thoughtful discussion.
There is a shared outlook that this research could significantly influence future cancer treatments, though some posts are more enthusiastic than analytical.
New #JITC article: Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects https://t.co/GgX1wOz4Lx https://t.co/fNoOHOUTZc
Explore the latest #JITC cutting-edge data with a new video abstract! Check out Acasunlimab + PD-1 Blockade: Combining Forces to Boost Anti-Tumor Immunotherapy here: https://t.co/DY7tJ68z4f
#Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects $GMAB #Genmab #DuoBody #GEN1046 https://t.co/yPA0vzfAf6
RT @jitcancer: New #JITC article: Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitum…
RT @jitcancer: New #JITC article: Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitum…
RT @jitcancer: New #JITC article: Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitum…
Acasunlimab, a bispecific antibody combining PD1 blockade with targeted T-cell activation via 41BB, enhances antitumor immunity by blocking inhibitory signals and stimulating immune responses. Combining it with PD-1…
Explore the latest #JITC cutting-edge data with a new video abstract! Check out Acasunlimab + PD-1 Blockade: Combining Forces to Boost Anti-Tumor Immunotherapy here: https://t.co/DY7tJ68z4f
#Acasunlimab + PD-1 Blockade: Combining Forces to Boost Anti-Tumor Immunotherapy @Genmab $GMAB #GEN1046 #DuoBody-PD-L1x4-1BB https://t.co/gXGpoJxKQd
RT @jitcancer: New #JITC article: Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitum…
RT @jitcancer: New #JITC article: Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitum…
RT @jitcancer: New #JITC article: Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitum…
RT @jitcancer: New #JITC article: Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitum…
New #JITC article: Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects https://t.co/GgX1wOz4Lx https://t.co/fNoOHOUTZc
#Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects $GMAB #Genmab #DuoBody #GEN1046 https://t.co/yPA0vzfAf6